Compare Cytokinetics Inc (CYTK) vs MINISO Group Holding Ltd (MNSO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs MINISO Group Holding Ltd — how do they compare? Cytokinetics Inc trades at $82.09 (market cap $11.12B), while MINISO Group Holding Ltd trades at $12.65 (market cap $3.46B). The key difference: Cytokinetics Inc is far larger — about 3.2× MINISO Group Holding Ltd's market cap, and MINISO Group Holding Ltd pays a 5.78% dividend while Cytokinetics Inc pays none. Which is the better fit depends on your goals.
| CYTK | MNSO | |
|---|---|---|
Market Cap | $11.12B | $3.46B |
Sector | Technology | Technology |
52-Week High | $87.26 | $26.63 |
52-Week Low | $33.23 | $11.30 |
Enterprise Value | $11.59B | $4.13B |
Dividend Yield | — | 5.78% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CYTK trades at $82.24, down 3.1% today, with a bullish technical outlook supported by moving averages and RSI near oversold levels. The company shows strong analyst support with 97% buy ratings and a $110.40 consensus target, but faces fundamental challenges with a -784% net income margin and negative cash flow from operations of -$510M in 2025. Recent positive developments include FDA approval and European launch of Myqorzo, driving commercial momentum.
Outlook remains speculative with high valuation (P/S 93.92) against significant losses, yet growth potential exists if Myqorzo gains market traction. Key risks include cash burn, competitive pressure, and reliance on single drug success. Institutional sentiment is overwhelmingly bullish, but investors must weigh high risk-reward profile amid ongoing profitability challenges.
MNSO trades at $11.42, down 3.14% on the day, reflecting recent volatility. The stock shows mixed signals with a bearish technical trend but solid fundamentals, including a P/E of 11.73 and net income margin of 8.98%. Recent corporate actions include a $0.38 dividend and a HK$2 billion share repurchase program announced on June 29, 2026, signaling management confidence. Q1 2026 earnings beat expectations with EPS of $0.591 versus $0.238 expected, though prior quarters missed estimates.
Outlook is cautiously optimistic given strong profitability metrics and shareholder-friendly actions, but risks include margin pressures from overseas expansion and technical bearishness. With 75% analyst buy ratings and an undervalued GF Score per GuruFocus on June 29, 2026, the stock offers value if execution improves, though investors should monitor earnings consistency and global economic headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About MINISO Group Holding Ltd
MINISO Group Holding Ltd is a global lifestyle product retailer known for its aesthetically pleasing, high-quality, and low-cost goods. The company operates a network of branded stores worldwide, offering a diverse range of merchandise, including household goods, cosmetics, toys, and digital accessories. MINISO's business model emphasizes rapid product iteration, efficient supply chain management, and a joint venture and franchise partner network to facilitate its global expansion.
Read more on MNSO →
